Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 5,916,054 | 5,649,649 | 5,355,946 | 5,479,628 | 5,157,364 |
| Cost of Goods | 961,899 | 960,957 | 899,169 | 941,963 | 897,111 |
| Gross Profit | 4,954,159 | 4,688,692 | 4,456,777 | 4,537,666 | 4,260,254 |
| Operating Expenses | 2,867,545 | 2,271,158 | 2,061,270 | 2,110,046 | 2,430,796 |
| Operating Income | 2,087,511 | 2,418,491 | 2,395,676 | 2,428,582 | 1,829,570 |
| Interest Expense | 121,519 | 147,022 | -7,781 | 129,194 | 89,823 |
| Other Income | 35,278 | 125,294 | 14,589 | 284,162 | 207,138 |
| Pre-tax Income | 2,001,270 | 2,396,763 | 2,418,046 | 2,583,550 | 1,946,885 |
| Income Tax | 336,531 | 474,690 | 452,907 | 537,362 | 434,628 |
| Net Income Continuous | 1,664,739 | 1,922,073 | 1,965,138 | 2,046,188 | 1,512,256 |
| Net Income | $1,664,739 | $1,922,073 | $1,965,138 | $2,046,188 | $1,512,256 |
| EPS Basic Total Ops | 0.36 | 0.42 | 0.43 | 0.44 | 0.33 |
| EPS Basic Continuous Ops | 0.37 | 0.42 | 0.43 | 0.44 | 0.33 |
| EPS Diluted Total Ops | 0.36 | 0.42 | 0.43 | 0.44 | 0.33 |
| EPS Diluted Continuous Ops | 0.36 | 0.42 | 0.43 | 0.44 | 0.33 |
| EBITDA(a) | $2,420,727 | $2,623,364 | $2,592,952 | $2,651,794 | $2,024,209 |